Little is known about what causes ovarian cancer, and there is no way to detect it early. Now, an accidental finding in a 22-year-old patient has given Mayo Clinic researchers a new lead.
First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.
